Ubs Group Ag Inhibikase Therapeutics, Inc. Transaction History

Ubs Group Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$0.45 - $5.41 $3,316 - $39,866	-7,369 Reduced 98.27%	130 $0
Q3 2022 Nov 10, 2022	BUY	$0.76 - $5.46 $5,699 - $40,944	7,499 New	7,499 $7,000
Q2 2022 Aug 10, 2022	SELL	$0.63 - $1.44 $3,220 - $7,361	-5,112 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.03 - $1.77 $3,453 - $5,934	3,353 Added 190.62%	5,112 $8,000
Q4 2021 Feb 14, 2022	SELL	$1.38 - $2.17 $9,368 - $14,732	-6,789 Reduced 79.42%	1,759 $3,000
Q3 2021 Nov 15, 2021	BUY	$1.79 - $2.81 $15,300 - $24,019	8,548 New	8,548 $16,000

1.03M

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $80.7M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.